Literature DB >> 31655119

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.

Jaime Sanz1, Juan Montoro2, Carlos Solano3, David Valcárcel4, Antonia Sampol5, Christelle Ferrá6, Rocío Parody7, Ignacio Lorenzo8, Pau Montesinos8, Guillermo Ortí4, Juan C Hernández-Boluda3, Aitana Balaguer-Roselló2, Manuel Guerreiro2, Carlos Carretero2, Guillermo F Sanz9, Miguel A Sanz9, José Luis Piñana8.   

Abstract

In this prospective randomized study, we compared the outcomes of single-unit umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (haplo-SCT) with post-transplantation cyclophosphamide (PTCy) in adults with hematologic malignancies. All patients received a myeloablative conditioning (MAC) regimen consisting of thiotepa, busulfan, and fludarabine, with antithymocyte globulin (ATG) added for UCBT recipients. Nineteen patients were randomized to UCBT and the other 26 to haplo-HSCT. Four patients (15%) allocated to the haplo-HSCT arm lacked a suitable donor and were crossed over to the UCBT arm. Finally, 23 underwent UCBT and 22 underwent haplo-HSCT. The cumulative incidence of neutrophil recovery was 87% at a median of 19 days (range, 13 to 24 days) in the UCBT arm versus 100% at a median of 17 days (range, 13 to 25 days) in the haplo-SCT arm (P = .04). Platelet recovery was 70% at a median of 40 days (range, 18 to 129 days) in the UCBT arm versus 86% at a median of 24 days (range, 12 to 127 days) in the haplo-HCT arm (P = .02). Rates of acute graft-versus-host disease (GVHD) grade II-IV or grade III-IV, overall chronic GVHD, and extensive chronic GVHD in the UCBT and Haplo-SCT arms were 43% versus 36% (P = .8), 9% versus 9% (P = 1), 66% versus 43% (P = .04), and 41% versus 23% (P = .2), respectively. Two-year nonrelapse mortality and relapse in the 2 arms were 52% versus 23% (P = .06) and 17% versus 23% (P = .5), respectively. Two-year disease-free survival, overall survival, and GVHD/relapse-free survival in the 2 arms were 30% versus 54% (P = .2), 35% versus 59% (P = .1), and 17% versus 40% (P = .04), respectively. Our data show that in the context of an MAC regimen, haplo-SCT with PTCy provides improved outcomes compared with ATG-containing single-unit UCBT.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic stem cell transplantation clinical trial; Alternative donor transplantation; Haploidentical transplantation; Hematologic malignancy; Umbilical cord blood transplantation

Mesh:

Year:  2019        PMID: 31655119     DOI: 10.1016/j.bbmt.2019.10.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

1.  Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101).

Authors:  Ephraim J Fuchs; Paul V O'Donnell; Mary Eapen; Brent R Logan; Joseph H Antin; Peter Dawson; Steven M Devine; Mary M Horowitz; Mitchell E Horwitz; Chatchada Karanes; Eric Leifer; John M Magenau; Joseph Patrick McGuirk; Lawrence E Morris; Andrew R Rezvani; Richard J Jones; Claudio G Brunstein
Journal:  Blood       Date:  2020-08-31       Impact factor: 22.113

Review 2.  Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications.

Authors:  Patricia A Shi; Larry L Luchsinger; John M Greally; Colleen S Delaney
Journal:  Curr Opin Hematol       Date:  2022-08-29       Impact factor: 3.218

3.  Real-world experience: Introduction of T cell replete haploidentical transplantations in a single center.

Authors:  Gwendolyn van Gorkom; Evy Billen; Catharina Van Elssen; Michel van Gelder; Gerard Bos
Journal:  EJHaem       Date:  2021-05-26

4.  Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.

Authors:  Juan Montoro; José Luis Piñana; Carlos Solano; Jaime Sanz; Juan C Hernández-Boluda; Rafael Hernani; Ignacio Lorenzo; Ariadna Pérez; Manuel Guerreiro; Aitana Balaguer-Rosello; Guillermo F Sanz; Carlos Carretero; Eliseo Albert; David Navarro; Miguel A Sanz
Journal:  Bone Marrow Transplant       Date:  2020-05-05       Impact factor: 5.483

5.  Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis.

Authors:  Ran Wu; Liyuan Ma
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 6.  KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection.

Authors:  Adèle Dhuyser; Alice Aarnink; Michaël Pérès; Jyothi Jayaraman; Neda Nemat-Gorgani; Marie Thérèse Rubio; John Trowsdale; James Traherne
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

7.  Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning.

Authors:  John E Wagner; Karen K Ballen; Mei-Jie Zhang; Mariam Allbee-Johnson; Chatchada Karanes; Filippo Milano; Michael R Verneris; Mary Eapen; Claudio G Brunstein
Journal:  Blood Adv       Date:  2021-10-26

8.  Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients.

Authors:  Linlin Jin; Zimin Sun; Huilan Liu; Xiaoyu Zhu; Yonggang Zhou; Binqing Fu; Xiaohu Zheng; Kaidi Song; Baolin Tang; Yun Wu; Jiang Zhu; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  Nat Commun       Date:  2021-07-06       Impact factor: 14.919

9.  Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.

Authors:  Ephraim J Fuchs; Paul V O'Donnell; Mary Eapen; Brent Logan; Joseph H Antin; Peter Dawson; Steven Devine; Mary M Horowitz; Mitchell E Horwitz; Chatchada Karanes; Eric Leifer; John M Magenau; Joseph P McGuirk; Lawrence E Morris; Andrew R Rezvani; Richard J Jones; Claudio G Brunstein
Journal:  Blood       Date:  2021-01-21       Impact factor: 25.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.